FDA Clears IND Application for FAP-Exatecan (AVA6103)
Christina Coughlin, MD, PhD, Chief Executive Officer at Avacta Therapeutics commented, “Taking FAP-Exd into the clinic is a critical milestone for the pre|CISION® platform and for the Company. In moving the FAP-Exd program forward from inception to a cleared IND in just 24 months, our team has exceeded industry standard timelines. The sustained release mechanism of FAP-Exd, invented by Avacta, is expected to enable greater efficacy in the clinic while limiting the toxicities that were observed with exatecan in its original clinical development. We are very excited to move this program forward for patients and shareholders alike.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo